NCT04679935 - Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions

Age-related Macular Degeneration

Interventions

BIOLOGICAL

Brolucizumab

Intravitreal injection

Trial Locations (19)

1000

Novartis Investigative Site, Lausanne

3007

Novartis Investigative Site, Bern

8063

Novartis Investigative Site, Zurich

13353

Novartis Investigative Site, Berlin

17036

Novartis Investigative Site, Neubrandenburg

23538

Novartis Investigative Site, Lübeck

30625

Novartis Investigative Site, Hanover

35039

Novartis Investigative Site, Marburg

37075

Novartis Investigative Site, Göttingen

39120

Novartis Investigative Site, Magdeburg

40225

Novartis Investigative Site, Düsseldorf

48149

Novartis Investigative Site, Münster

53105

Novartis Investigative Site, Bonn

55131

Novartis Investigative Site, Mainz

60549

Novartis Investigative Site, Frankfurt am Main

66421

Novartis Investigative Site, Homburg

89075

Novartis Investigative Site, Ulm

93053

Novartis Investigative Site, Regensburg

04103

Novartis Investigative Site, Leipzig